Administration of antidepressants

Yýldýz, Ayşegül; Sachs, Gary S.

doi:10.1016/s0165-0327(00)00307-4

Cited by 19 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evening versus morning administration of duloxetine results in a three-hour delay in absorption and an approximately 33% increase in clearance 39. The plasma and elimination half-lives of duloxetine are approximately 12 hours 40. However, because duloxetine is able to cross the blood–brain barrier, its plasma half-life in the central nervous system (CNS) may be longer than in the peripheral measures typically reported.…”

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

Recla¹

2010

JPR

View full text Add to dashboard Cite

Fibromyalgia (FM) is a chronic widespread pain condition that is estimated to affect 5 million US adults. Several molecular pathophysiologies are thought to contribute to the symptoms of FM, complicating the development of effective clinical management techniques. It is now known that abnormalities in both nociceptive and central pain processing systems are necessary (but perhaps not sufficient) to condition the onset and maintenance of FM, producing associated neuropsychologic symptoms such as pronounced fatigue, sleep abnormalities, cognitive difficulties, stress sensitivity, anxiety, and depression. Current treatment strategies are focused primarily on correcting the pathophysiologic mechanisms underlying these nervous system abnormalities. Clinical studies demonstrate the safety and efficacy of three drugs recently approved for the treatment of FM: pregabalin (an alpha-2-delta ligand), and duloxetine and milnacipran (serotonin/norepinephrine reuptake inhibitors). This review describes these pharmaceuticals in detail and discusses their current roles in FM management.

show abstract

Section: Pharmacology and Pharmacokineticsmentioning

confidence: 99%

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

Recla¹

2010

JPR

View full text Add to dashboard Cite

show abstract

PROTOCOL: Treatment for depressive disorder among adults: An evidence and gap map of systematic reviews

Guo

White

et al. 2023

Campbell Systematic Reviews

View full text Add to dashboard Cite

show abstract

Current Awareness

2002

Human Psychopharmacology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of human psychopharmacology. Each bibliography is divided into 18 sections: 1 Books, Reviews & Symposia; 2 General; 3 Psychotropic Drugs ‐ General; Antidepressive Agents: 4 Tricyclics; 5 Monoamine Oxidase Inhibitors; 6 Serotonergics; Euthymic Agents: 7 Lithium; Tranquillizing Agents: 8 Major; 9 Minor & Hypnotics; 10 Analeptic Agents; 11 Anticonvulsant Agents; 12 Drugs of Abuse; 13 Transmitters, Receptors, Metabolites & Modulating Agents; 14 Neuropeptides; 15 Psychoneuroendocrinology; 16 Psychoneuroimmunology; 17 Behavioural Genetics; 18 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Administration of antidepressants

Cited by 19 publications

References 26 publications

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

PROTOCOL: Treatment for depressive disorder among adults: An evidence and gap map of systematic reviews

Current Awareness

Contact Info

Product

Resources

About